NASDAQ

Beta Bionics, Inc. (BBNX)

621 Thanks from members

Beta Bionics (BBNX) displays a tension between strong 57% YoY revenue growth, improved gross margins, and a $240M cash buffer, versus escalating operating expenses, legal/regulatory investigations, and fierce competition.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →